

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/475,158	12/30/1999	Thomas J. Gardella	0609.4780001 6018		
26111 7	590 02/17/2004		EXAMINER		
STERNE, KESSLER, GOLDSTEIN & FOX PLLC 1100 NEW YORK AVENUE, N.W.			LI, RUIXIANG		
	N, DC 20005		ART UNIT PAPER NUMBER		
	.,		1646		
			DATE MAILED: 02/17/200-	4	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
Advisory Action	09/475,158	GARDELLA ET AL.			
Advisory Action	Examiner	Art Unit			
	Ruixiang Li	1646			
The MAILING DATE of this communication appe	ears on the cover sheet with the c	orrespondence add	ress		
THE REPLY FILED 02 January 2004 FAILS TO PLACE Therefore, further action by the applicant is required to a virial rejection under 37 CFR 1.113 may only be either: (1) condition for allowance; (2) a timely filed Notice of Appea Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this applica ) a timely filed amendment which I (with appeal fee); or (3) a timel	ation. A proper repl n places the applica	y to a ation in		
	EPLY [check either a) or b)]				
a) The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire I ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The fee have been filed is the date for purposes of determining the period of the under 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment. See 37 CFR 1.17(a) is calculated from: (1) the expiration date of (2) as set forth in (b) above, if checked. Any reply received by the Officinely filed, may reduce any earned patent term adjustment.	Advisory Action, or (2) the date set forth later than SIX MONTHS from the mailing SFILED WITHIN TWO MONTHS OF THE date on which the petition under 37 CF of extension and the corresponding amount the shortened statutory period for reply ce later than three months after the mai	g date of the final rejecti HE FINAL REJECTION. R 1.136(a) and the appr unt of the fee. The app originally set in the final	on. See MPEP ropriate extension ropriate extension Office action; or		
1. A Notice of Appeal was filed on Appellant's 37 CFR 1.192(a), or any extension thereof (37 CFR	s Brief must be filed within the pe R 1.191(d)), to avoid dismissal o	eriod set forth in f the appeal.			
2. The proposed amendment(s) will not be entered be	ecause:				
(a) \( \square\) they raise new issues that would require further	er consideration and/or search (	see NOTE below);			
(b) ☐ they raise the issue of new matter (see Note below);					
<ul><li>(c)  they are not deemed to place the application is issues for appeal; and/or</li></ul>					
(d) ☑ they present additional claims without canceling a corresponding number of finally rejected claims.					
NOTE: <u>See Continuation Sheet</u> .					
3. Applicant's reply has overcome the following reject					
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	·				
5. ☐ The a) ☐ affidavit, b) ☐ exhibit, or c) ☐ request for application in condition for allowance because: See	reconsideration has been consi te Continuation Sheet.	idered but does NO	T place the		
6. The affidavit or exhibit will NOT be considered bed raised by the Examiner in the final rejection.	ause it is not directed SOLELY t	to issues which wer	e newly		
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	t(s) a)⊠ will not be entered or b ould be rejected is provided belo	)□ will be entered a ow or appended.	and an		
The status of the claim(s) is (or will be) as follows:					
Claim(s) allowed:	•				
Claim(s) objected to:					
Claim(s) rejected: <u>1-11,14 and 37</u> .					
Claim(s) withdrawn from consideration:					
8. $\square$ The drawing correction filed on is a) $\square$ app	roved or b)  disapproved by t	he Examiner.			
9. Note the attached Information Disclosure Stateme	nt(s)( PTO-1449) Paper No(s)	·			
10. Other:					
	PRIMA <b>R</b>	NE J. SAOUD Y EXAMINER			
	Chira	tin D. Sa	aud		

## **Continuation Sheet (PTOL-303)**

Continuation of 2. NOTE: the amended claim 1 has added, in part, the following limitations: (i) wherein said compound has a biological activity substantialy similar to PTH(1-34) or PTHrP(1-34); and (ii) wherein said linker is selected from the group comprising an amio acid and an aliphatic diamine. The limitation (i) raises the issue of indefiniteness under 35 U.S.C. 112, 2nd paragraph since the term "substantially" is not defined in the specification and it is not clear what are the metes and bounds of the term, rendering the claim indefinite. Limitation (ii) raises a new issue, which requires new search and consideration.

Furthermore, the proposed amendment presents two new claims without canceling a corresponding number of finally rejected claims.

Continuation of 5. does NOT place the application in condition for allowance because: the rejection of claims 1-11, 14, and 37 under 35 U.S.C. 112, 1st paragraph for scope of enablement remains.

Applicants argue that Applicants have amended the claim 1 to address the Examiner's concerns that there is no specific functional limitation for the claimed compounds. This is not persuasive because the the newly added limitation does not define a specific, meaningful biological function. In addition, the limitation raised an indefiniteness issue as noted above.

Applicants argue that Applicants have amended the claim 1 to overcome the rejection over the issue of the undefined linker. This is not persuasive because the scope of the linker recited in the amended claim is still too broad. Needless to say the type of the linker, even the length of the linker is undefined.